Multi-omics analysis provides new insights into mechanism of didymin on non-alcoholic fatty liver disease in rats

被引:1
|
作者
Fang, Bin [1 ]
Mo, Rou [1 ]
Lin, Xing [1 ]
Huang, Quanfang [2 ]
Huang, Renbin [1 ]
机构
[1] Guangxi Med Univ, Nanning 530021, Guangxi, Peoples R China
[2] Guangxi Univ Chinese Med, Affiliated Hosp 1, Nanning 530023, Guangxi, Peoples R China
关键词
Didymin; NAFLD; Multi-Omics analysis; PPAR; Insulin; ENDOPLASMIC-RETICULUM STRESS; METABOLISM; ACID;
D O I
10.1016/j.phymed.2024.156016
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases accompanied by lipid and glucose metabolism disorder. Didymin has been reported to have various hepatoprotective effects, however, its potential effects and mechanisms on NAFLD remain unclear from the perspective of the whole. Purpose: To investigate the underlying mechanism of didymin against NAFLD using multi-omics technologies. Methods: Rats were fed with a high-fat diet (HFD) for 8 weeks to induce NAFLD, followed by didymin treatment for 8 weeks. Next, biochemical analysis and histopathological examinations were performed to evaluate the effects of didymin. The key regulating pathways were predicted using transcriptomics, metabolomics and proteomics, and the target pathways were then verified by detecting the key genes/proteins using various experiments. Results: Didymin markedly mitigated liver injury and excessive lipid droplet accretion. An integrative multiomics analysis suggested that the PPAR signaling cascade and insulin signaling pathway might serve as pivotal mechanisms underlying the modulation of lipid and glucose homeostasis by didymin. Further dissection identified five pivotal genes (PPAR alpha, PPAR beta, FABP4, ANGPTL4, and PLIN2) and four genes (HK1, HK3, GCK, and PTPN1) as potential hubs within these pathways. Subsequent validation experiments, including qPCR and Western blot, demonstrated upregulated expression of PPAR alpha and PPAR beta, indicating the activation of the PPAR pathway by didymin. Concurrently, didymin appeared to modulate the insulin signaling pathway, as evidenced by the upregulated expression of HK1 and downregulated expression of PTPN1. Notably, the manipulation of PPAR alpha, PPAR beta, and PTPN1 expression in LO2 cells through silence or overexpression confirmed that didymin significantly reduced lipid accumulation, with its molecular targets likely being the PPAR and insulin pathways. Conclusions: Our findings demonstrate that didymin has a protective effect on NAFLD, and its underlying mechanism may be associated with the regulation of the PPAR and insulin signaling pathways.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Non-alcoholic fatty liver disease
    Alba, LM
    Lindor, K
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) : 977 - 986
  • [42] Non-alcoholic fatty liver disease
    Sattar, Naveed
    Forrest, Ewan
    Preiss, David
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [43] Non-alcoholic fatty liver disease
    Li, Wenhao
    Alazawi, William
    CLINICAL MEDICINE, 2020, 20 (05) : 509 - 512
  • [44] Multi-Omics Integration Analysis Identifies Lipid Disorder of a Non-Alcoholic Fatty Liver Disease (NAFLD) Mouse Model Improved by Zexie-Baizhu Decoction
    Cao, Yuhan
    Shi, Jingying
    Song, Luyao
    Xu, Junjiu
    Lu, Henglei
    Sun, Jianhua
    Hou, Jinjun
    Chen, Jing
    Wu, Wanying
    Gong, Likun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [45] Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring
    Long, Michelle T.
    Gurary, Ellen B.
    Massaro, Joseph M.
    Ma, Jiantao
    Hoffmann, Udo
    Chung, Raymond T.
    Benjamin, Emelia J.
    Loomba, Rohit
    LIVER INTERNATIONAL, 2019, 39 (04) : 740 - 747
  • [46] Advancing insights into non-alcoholic fatty liver disease: A critical analysis of ultrasonography and beyond
    Ghonge, Swati
    Vajjala, Sai Mahesh
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2024, 13 (08) : 3461 - 3462
  • [47] Recent insights on the role of cholesterol in non-alcoholic fatty liver disease
    Arguello, Graciela
    Balboa, Elisa
    Arrese, Marco
    Zanlungo, Silvana
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2015, 1852 (09): : 1765 - 1778
  • [48] Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease
    Lee, Jin
    Park, Jeong-Su
    Roh, Yoon Seok
    ARCHIVES OF PHARMACAL RESEARCH, 2019, 42 (11) : 935 - 946
  • [49] Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Eslami, Layli
    Merat, Shahin
    Malekzadeh, Reza
    Nasseri-Moghaddam, Siavosh
    Aramin, Hermineh
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [50] Insights in non-alcoholic fatty liver disease pathophysiology with lipidomic analyses
    Almeda-Valdes, Patoma
    Altamirano-Barrera, Alejandra
    Mendez-Sanchez, Nahum
    ANNALS OF HEPATOLOGY, 2015, 14 (04) : 567 - 569